Literature DB >> 24197801

Novel SMARCAL1 bi-allelic mutations associated with a chromosomal breakage phenotype in a severe SIOD patient.

Amos J Simon1, Atar Lev, Marta Jeison, Zvi U Borochowitz, David Korn, Yaniv Lerenthal, Raz Somech.   

Abstract

PURPOSE: Chromosomal instability syndromes include a group of rare diseases characterized by defective DNA-damage-response and increased risk of chromosomal breakage. Patients display defects in the recognition and/or repair of DNA damage, with a subsequent high rate of malignancies and abnormal gene rearrangements. Other clinical manifestations, such as immunodeficiency, neurodevelopmental delay and skeletal abnormalities, are present in some of these syndromes. We studied a patient with profound T-lymphocyte defect, neurodevelopmental delay, facial dysmorphism, nephrotic syndrome and spondyloepiphyseal bone dysplasia typical of SIOD.
METHODS: Karyotype and chromosome fragility assays on patients' peripheral blood mononuclear cells showed an abnormal rate of spontaneous breaks. Cell cycle analysis of patient's fibroblasts following replication stress induced by hydroxyhurea revealed a delay in their release from S-phase to G2. When using higher concentrations of hydroxyhurea no patient fibroblast colonies could survive, compared with control fibroblasts. Whole-exome sequencing revealed novel compound heterozygote mutations in SMARCAL1 gene, resulting in putative frame shifts of encoded SMARCAL1 from each allele and no detected protein in patient's cells. The patient's youngest brother was found to have similar manifestations of SIOD but of less severity, including short stature, facial dysmorphism and typical osseous dysplasia, but no clinical findings suggestive of immunodeficiency and no chromosomal fragility. Similar to his sister, the brother carries both bi-allelic mutations in SMARCAL1 gene.
CONCLUSIONS: We present here the first evidence of intrinsic chromosomal instability in a severe SMARCAL1-deficient patient with a clinical picture of SIOD. Our results are consistent with the recently outlined role of SMARCAL1 protein in DNA damage response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24197801     DOI: 10.1007/s10875-013-9957-3

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  23 in total

1.  Schimke immuno-osseous dysplasia: SMARCAL1 loss-of-function and phenotypic correlation.

Authors:  L I Elizondo; K S Cho; W Zhang; J Yan; C Huang; Y Huang; K Choi; E A Sloan; K Deguchi; S Lou; A Baradaran-Heravi; H Takashima; T Lücke; F A Quiocho; C F Boerkoel
Journal:  J Med Genet       Date:  2008-09-19       Impact factor: 6.318

2.  Prenatal and postnatal diagnosis and carrier detection of Fanconi anemia by a cytogenetic method.

Authors:  A D Auerbach; B Adler; R S Chaganti
Journal:  Pediatrics       Date:  1981-01       Impact factor: 7.124

3.  The Sequence Alignment/Map format and SAMtools.

Authors:  Heng Li; Bob Handsaker; Alec Wysoker; Tim Fennell; Jue Ruan; Nils Homer; Gabor Marth; Goncalo Abecasis; Richard Durbin
Journal:  Bioinformatics       Date:  2009-06-08       Impact factor: 6.937

4.  DEB test for Fanconi anemia detection in patients with atypical phenotypes.

Authors:  Carmen Esmer; Silvia Sánchez; Sandra Ramos; Bertha Molina; Sara Frias; Alessandra Carnevale
Journal:  Am J Med Genet A       Date:  2004-01-01       Impact factor: 2.802

5.  Identification of SMARCAL1 as a component of the DNA damage response.

Authors:  Lisa Postow; Eileen M Woo; Brian T Chait; Hironori Funabiki
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 6.  DNA strand break repair and human genetic disease.

Authors:  Peter J McKinnon; Keith W Caldecott
Journal:  Annu Rev Genomics Hum Genet       Date:  2007       Impact factor: 8.929

7.  Fanconi's anemia: a cytogenetic study on lymphocyte and bone marrow cultures utilizing 1,2:3,4-diepoxybutane.

Authors:  M P Marx; S Smith; A D Heyns; I Z van Tonder
Journal:  Cancer Genet Cytogenet       Date:  1983-05

8.  Molecular assessment of thymic capacities in patients with Schimke immuno-osseous dysplasia.

Authors:  Atar Lev; Ninette Amariglio; Yael Levy; Zvi Spirer; Yair Anikster; Gideon Rechavi; Benjamin Dekel; Raz Somech
Journal:  Clin Immunol       Date:  2009-09-30       Impact factor: 3.969

9.  Schimke Immunoosseous Dysplasia associated with undifferentiated carcinoma and a novel SMARCAL1 mutation in a child.

Authors:  Clinton Carroll; Akosua Badu-Nkansah; Tracy Hunley; Alireza Baradaran-Heravi; David Cortez; Haydar Frangoul
Journal:  Pediatr Blood Cancer       Date:  2013-04-29       Impact factor: 3.167

10.  Identification of multiple distinct Snf2 subfamilies with conserved structural motifs.

Authors:  Andrew Flaus; David M A Martin; Geoffrey J Barton; Tom Owen-Hughes
Journal:  Nucleic Acids Res       Date:  2006-05-31       Impact factor: 16.971

View more
  5 in total

1.  A structure-specific nucleic acid-binding domain conserved among DNA repair proteins.

Authors:  Aaron C Mason; Robert P Rambo; Briana Greer; Michael Pritchett; John A Tainer; David Cortez; Brandt F Eichman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

2.  Smarcal1 promotes double-strand-break repair by nonhomologous end-joining.

Authors:  Islam Shamima Keka; Yuko Maede; Md Maminur Rahman; Tetsushi Sakuma; Masamitsu Honma; Takashi Yamamoto; Shunichi Takeda; Hiroyuki Sasanuma
Journal:  Nucleic Acids Res       Date:  2015-06-18       Impact factor: 16.971

3.  HARP preferentially co-purifies with RPA bound to DNA-PK and blocks RPA phosphorylation.

Authors:  Jinhua Quan; Timur Yusufzai
Journal:  Epigenetics       Date:  2014-02-24       Impact factor: 4.528

4.  A novel compound heterozygous mutation of the SMARCAL1 gene leading to mild Schimke immune-osseous dysplasia: a case report.

Authors:  Shuaimei Liu; Mingchao Zhang; Mengxia Ni; Peiran Zhu; Xinyi Xia
Journal:  BMC Pediatr       Date:  2017-12-28       Impact factor: 2.125

5.  The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.

Authors:  Bill H Diplas; Xujun He; Jacqueline A Brosnan-Cashman; Heng Liu; Lee H Chen; Zhaohui Wang; Casey J Moure; Patrick J Killela; Daniel B Loriaux; Eric S Lipp; Paula K Greer; Rui Yang; Anthony J Rizzo; Fausto J Rodriguez; Allan H Friedman; Henry S Friedman; Sizhen Wang; Yiping He; Roger E McLendon; Darell D Bigner; Yuchen Jiao; Matthew S Waitkus; Alan K Meeker; Hai Yan
Journal:  Nat Commun       Date:  2018-05-25       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.